Risen (Suzhou) Pharma Tech is the lead sponsor of 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Fulvestrant, JS105 and Capecitabine. The most-studied condition is Mild Cognitive Impairment (MCI).
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
To Evaluate the Safety and Efficacy of RP902 Tablets
NCT07579884 · ClinicalTrials.gov ↗ · Mild Cognitive Impairment (MCI)
|
Phase 2 | Recruiting | 2026-07 | China |
|
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
NCT07207070 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 3 | Recruiting | 2025-11 | China |
|
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
NCT06208410 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1/2 | Recruiting | 2024-01 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Risen (Suzhou) Pharma Tech is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 5 October 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 9 drugs and biologicals as interventions. The most frequent are Fulvestrant (2), JS105 (2), Capecitabine (1), Dalpiciclib (1) and Dalpiciclib Isetionate (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 5 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
